Bleeding

Also known as: Bleed / Hemorrhage term / Hem / Hemorrhage, unspecified / Haemorrhage, unspecified / Extravasation blood / Blood loss of (NOS) / Hemorrhage NOS / Haemorrhage / Haemorrhage NOS / Hemorrhage (NOS) / Hemorrhage

DrugDrug NameDrug Description
DB00513Aminocaproic AcidAn antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
DB09329Antihemophilic Factor (Recombinant), PEGylatedAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. Antihemophilic Factor (Recombinant), PEGylated, is a recombinant full-length human coagulation factor VIII (2,332 amino acids with a molecular weight (MW) of approximately 280 kDa) covalently conjugated with at least one molecule of polyethylene glycol (MW 20 kDa) [FDA label]. It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label]. PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529].
DB00025Antihemophilic factor, human recombinantHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
DB09310Coagulation Factor XIII A-Subunit (Recombinant)Coagulation Factor XIII A-Subunit (Recombinant), also known as catridecacog, is a recombinant form of the Factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential for management and prevention of bleeding episodes. Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously available coagulation factor and the final enzyme within the blood coagulation cascade. Within the body, FXIII circulates as a heterotetramer composed of 2 catalytic A-subunits and 2 non-catalytic B-subunits (FXIII-A2B2) [A32363]. When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. As a result, the active transglutaminase from subunit A cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. This contributes to enhanced platelet and clot adhesion to injured tissue, thereby improving blood coagulation and maintenance of hemostasis [A18581]. When supplied as the recombinant form, Coagulation Factor XIII A-Subunit (Recombinant) binds to free human FXIII B-subunit resulting in a heterotetramer (rA2B2) with a similar activity profile and half-life as the endogenously available form. In patients with congenital factor XIII A-subunit deficiency, this product (marketed as Tretten) is indicated for the routine prophylaxis of bleeding. In these patients, activated rFXIII has been shown to increase the mechanical strength of fibrin clots, slow down fibrinolysis, and to enhance platelet adhesion to the site of injury. As the half-life of endogenous Factor XIII is long (5-11 days), prophylactic therapy with the replacement of FXIII can be given every 4-6 to maintain hemostasis[A32363]. Other drug products with similar structure and function to Coagulation Factor XIII A-Subunit (Recombinant) include [DB12909], which is a purified endogenous (human) form of coagulation factor XIII. Compared to Coagulation Factor XIII A-Subunit (Recombinant), which is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated, the human form is isolated from pooled human plasma. Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. Tretten is manufactured as an intracellular, soluble protein in yeast (Saccharomyces cerevisiae) production strain containing the episomal expression vector, pD16. It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography [FDA Label].
DB00036Coagulation factor VIIa Recombinant HumanRecombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
DB00035DesmopressinDesmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney [T28]. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH [A31661]. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate [A31662]. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate. Nocdurna, or desmopressin acetate, was approved by the FDA on June 21st, 2018 for the treatment of nocturia due to nocturnal polyuria in adults. It is available as a sublingual tablet.
DB11607Efmoroctocog alfaEfmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as [DB13999][A31551]. It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII. Patients with this disorder are more susceptible to recurrent bleeding episodes and excessive bleeding following minor traumatic injuries or surgical procedures [A31551]. Prophylactic treatment may dramatically improve the management of severe haemophilia A in the future by reducing joint bleeding and other hemorrhages that cause chronic pain and disability to patients [A31551, A31552]. Prophylaxis has also shown to reduce the formation of neutralizing anti-FVIII antibodies, or inhibitors [A31552]. Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. Efmoroctocog alfa is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [FDA Label]. The B domain of factor VIII is deleted. In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551]. Other drug products with similar structure and function to Efmoroctocog alfa include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. It is commonly marketed as Elocta or Eloctate for intravenous injection. To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected in the patient populations being studied [A31551]. The extended half-life of efmoroctocog alfa provides several clinical benefits for patients, including reduced frequency of injections required and improved adherence to prophylaxis [A31551].
DB11608Eftrenonacog alfaEftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H) [A31556]. The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved adherence to prophylaxis. Hemophilia B is a blood disorder with an incidence of approximately once every 30,000 male births in all populations and ethnic groups [A31557]. It is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding episodes caused spontaneously or as a result of accidental or surgical trauma [FDA Label]. When untreated, most patients die from bleeding complications before 25 years of age [A31557]. Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis. Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. Eftrenonacog alfa treatment demonstrated good tolerability with no reports of inhibitor development in clinical studies [A31556].
DB11330Factor IX Complex (Human)Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma. Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin. Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated. Although Factor IX Complex products contain many different coagulation components, Factor IX is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated with Hemophilia B (Factor IX deficiency). As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients experiencing acute major bleeding or requiring rapid reversal of therapy.
DB13998Lonoctocog alfaNot Available
DB13999Moroctocog alfaMoroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. Moroctocog alfa is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function. Moroctocog alfa is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein [FDA Label]. Clinical evaluation has shown that BDDrFVIII is pharmacokinetically equivalent to full-length recombinant FVIII [A32468, FDA Label]. Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as a co-factor to Factor IX. Activation of Factor IX leads to a cascade of signals that results in activation of Factor X, which then results in the conversion of prothrombin to thrombin, and as a result, leads to the conversion of fibrinogen to fibrin, the fibrous protein that creates the scaffold of the clot. Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein. Congenital loss or deficiency of Factor VIII results in the physiologic impairment of the coagulation clotting cascade, and as a result, leads to easy bruising and bleeding. Bleeding can range in severity from minor concerns, such as nosebleeds, to more serious events such as hemorrhaging in the joints, brain, or digestive tract [A32280]. Exogenous replacement of Factor VIII is currently the cornerstone of Hemophilia treatment and is used for the prophylaxis and control of bleeding episodes. Treatment has drastically improved since the 1960s when Factor VIII protein was primarily purified from human plasma, rather than being produced through recombinant DNA technology. Unfortunately, purification of protein from human plasma carries an increased risk of transmission of blood-borne diseases such as HIV and Hepatitis, which in part contributed to the Tainted Blood Scandal in the 1980s [A31551, A32272, L2177]. Use of recombinant DNA-derived clotting factor treatments, such as Moroctocog alfa, has reduced this risk. Other drug products with similar structure and function to Moroctocog alfa include [DB13192], which is purified Factor VIII from human pooled blood and contains both A- and B-subunits, and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [A31551]. Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia). As it does not contain von Willebrand factor it is not indicated in von Willebrand’s disease [FDA Label].
DB00325NitroprussideNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
DB13933Nonacog beta pegolNonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG are cleaved to leave the activated factor IX (Factor IXa).[A31496] Nonacog beta pegol was developed by Novo Nordisk, obtained EMA marketing authorisation in June 6, 2017.[L1099]
DB09108Simoctocog AlfaSimoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. As patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures. Simoctocog alfa is a glycoprotein consisting of 1440 amino acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and replaced by a 16 amino acid linker. Simoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]. Simoctocog alfa is marketed in Europe under the trade name Nuwiq for intravenous injection.
DB11606Susoctocog alfaIntravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of factor VIII. Patients with AHA have normal Factor VIII genes for coagulation pathways but develop inhibitory autoantibodies directed against Factor VIII. These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this procoagulant protein. Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis. In a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129]. Susoctocog alfa is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker. Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection. It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical assessments [L1129]. The recombinant porcine sequence allows less susceptibility to inactivation by circulating human factor VIII antibodies.
DB00302Tranexamic acidAntifibrinolytic hemostatic used in severe hemorrhage.
DB09109Turoctocog alfaTuroctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification process allowing isolation of the intact rFVIII.[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]
DB13133Von Willebrand Factor Humanvon Willebrand Factor (vWF) is a multimeric glycoprotein that consists of disulfide-bridge linked dimers. It is usually circulating in plasma as a stable complex with the coagulation factor VIII. The human vWF, as a drug product, is a complex that also contains the coagulation factor VIII.[A32268] This complex was developed by Octapharma Pharmazeutika Produktionsges and FDA approved on August 21, 2015.[L1878]
DB12872Vonicog AlfaVonicog Alfa is a recombinant von Willebrand factor manufactured by Baxalta. It was FDA approved in December 2015.[A32230] The gen of von Willebrand factor was first cloned in 1985 by Stuart Orkin and David Ginsburg.[L1849] By the EMA, vonicog alfa is still under clinical analysis.[L1862]
DrugDrug NameTargetType
DB00513Aminocaproic AcidPlasminogentarget
DB00513Aminocaproic AcidTissue-type plasminogen activatortarget
DB00513Aminocaproic AcidApolipoprotein(a)target
DB00513Aminocaproic AcidAldehyde oxidaseenzyme
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factortarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factorcarrier
DB00025Antihemophilic factor, human recombinantCoagulation factor Xtarget
DB00025Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB00025Antihemophilic factor, human recombinantCoagulation factor IXtarget
DB00025Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
DB00025Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
DB00025Antihemophilic factor, human recombinantCalreticulintarget
DB00025Antihemophilic factor, human recombinantCalnexintarget
DB00025Antihemophilic factor, human recombinantProtein ERGIC-53target
DB00025Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
DB00025Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
DB00025Antihemophilic factor, human recombinantvon Willebrand factortarget
DB00025Antihemophilic factor, human recombinantProthrombinenzyme
DB00025Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
DB09310Coagulation Factor XIII A-Subunit (Recombinant)Coagulation factor XIII B chaintarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factortarget
DB00036Coagulation factor VIIa Recombinant HumanSerine protease hepsintarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
DB00036Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
DB00035DesmopressinVasopressin V1a receptortarget
DB00035DesmopressinVasopressin V1b receptortarget
DB00035DesmopressinVasopressin V2 receptortarget
DB00035DesmopressinProstaglandin G/H synthase 1enzyme
DB00035DesmopressinProstaglandin G/H synthase 2enzyme
DB11607Efmoroctocog alfavon Willebrand factortarget
DB13998Lonoctocog alfaCoagulation factor Xtarget
DB13998Lonoctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB13998Lonoctocog alfaCoagulation factor IXtarget
DB13998Lonoctocog alfaAsialoglycoprotein receptor 2target
DB13998Lonoctocog alfa78 kDa glucose-regulated proteintarget
DB13998Lonoctocog alfaCalreticulintarget
DB13998Lonoctocog alfaCalnexintarget
DB13998Lonoctocog alfaProtein ERGIC-53target
DB13998Lonoctocog alfaProlow-density lipoprotein receptor-related protein 1target
DB13998Lonoctocog alfaMultiple coagulation factor deficiency protein 2target
DB13998Lonoctocog alfavon Willebrand factortarget
DB13998Lonoctocog alfaProthrombinenzyme
DB13998Lonoctocog alfaVitamin K-dependent protein Cenzyme
DB13999Moroctocog alfaCoagulation factor Xtarget
DB13999Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB13999Moroctocog alfaCoagulation factor IXtarget
DB13999Moroctocog alfaAsialoglycoprotein receptor 2target
DB13999Moroctocog alfa78 kDa glucose-regulated proteintarget
DB13999Moroctocog alfaCalreticulintarget
DB13999Moroctocog alfaCalnexintarget
DB13999Moroctocog alfaProtein ERGIC-53target
DB13999Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
DB13999Moroctocog alfaMultiple coagulation factor deficiency protein 2target
DB13999Moroctocog alfavon Willebrand factortarget
DB13999Moroctocog alfaProthrombinenzyme
DB13999Moroctocog alfaVitamin K-dependent protein Cenzyme
DB00325NitroprussideAtrial natriuretic peptide receptor 1target
DB00325NitroprussideCytochrome P450 1A1enzyme
DB13933Nonacog beta pegolCoagulation factor VIItarget
DB13933Nonacog beta pegolCoagulation factor VIIItarget
DB13933Nonacog beta pegolCoagulation factor Xtarget
DB09108Simoctocog Alfavon Willebrand factortarget
DB11606Susoctocog alfavon Willebrand factortarget
DB00302Tranexamic acidPlasminogentarget
DB00302Tranexamic acidSolute carrier family 15 member 2transporter
DB09109Turoctocog alfaCoagulation factor IXtarget
DB09109Turoctocog alfaCoagulation factor Xtarget
DB09109Turoctocog alfaProthrombintarget
DB13133Von Willebrand Factor HumanCoagulation factor VIIItarget
DB13133Von Willebrand Factor HumanCollagen alpha-1(I) chaintarget
DB13133Von Willebrand Factor HumanA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
DB12872Vonicog AlfaCoagulation factor VIIItarget
DB12872Vonicog AlfaCollagen alpha-1(I) chaintarget
DB12872Vonicog AlfaA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
DrugDrug NamePhaseStatusCount
DB14562Andexanet alfa1Completed1
DB06605Apixaban1Completed1
DB00035Desmopressin1Completed1
DB09075Edoxaban1Completed2
DB01225Enoxaparin1Completed1
DB06228Rivaroxaban1Completed1
DB00945Acetylsalicylic acid1 / 2Recruiting1
DB00758Clopidogrel1 / 2Recruiting1
DB09222Fibrinogen Human1 / 2Completed1
DB14562Andexanet alfa2Recruiting2
DB06605Apixaban2Recruiting1
DB06695Dabigatran etexilate2Terminated1
DB09075Edoxaban2Recruiting1
DB06210Eltrombopag2Active Not Recruiting1
DB11330Factor IX Complex (Human)2Not Yet Recruiting1
DB09222Fibrinogen Human2Completed1
DB09539Omega-3-acid ethyl esters2Completed1
DB00946Phenprocoumon2Terminated1
DB06228Rivaroxaban2Recruiting1
DB09153Sodium Chloride2Completed1
DB00675Tamoxifen2Active Not Recruiting1
DB00302Tranexamic acid2Completed1
DB00302Tranexamic acid2Terminated1
DB00682Warfarin2Terminated1
DB00668Epinephrine2 / 3Recruiting1
DB00945Acetylsalicylic acid3Not Yet Recruiting1
DB00006Bivalirudin3Completed1
DB00736Esomeprazole3Completed2
DB09222Fibrinogen Human3Completed1
DB09222Fibrinogen Human3Recruiting1
DB01109Heparin3Completed1
DB11571Human Thrombin3Completed1
DB00125L-Arginine3Completed1
DB00448Lansoprazole3Terminated1
DB00929Misoprostol3Completed1
DB01022Phylloquinone3Completed2
DB06228Rivaroxaban3Not Yet Recruiting1
DB00302Tranexamic acid3Not Yet Recruiting1
DB08867Ulipristal3Completed1
DB00682Warfarin3Completed1
DB00682Warfarin3Not Yet Recruiting1
DB00945Acetylsalicylic acid4Completed2
DB00945Acetylsalicylic acid4Recruiting1
DB01282Carbetocin4Completed1
DB00758Clopidogrel4Completed1
DB00758Clopidogrel4Recruiting1
DB00758Clopidogrel4Terminated1
DB13150Coagulation factor VII human4Enrolling by Invitation1
DB00304Desogestrel4Unknown Status1
DB09341Dextrose, unspecified form4Not Yet Recruiting1
DB01225Enoxaparin4Completed1
DB00294Etonogestrel4Unknown Status1
DB11330Factor IX Complex (Human)4Enrolling by Invitation1
DB01109Heparin4Not Yet Recruiting1
DB01109Heparin4Recruiting1
DB00107Oxytocin4Completed1
DB00213Pantoprazole4Completed1
DB06209Prasugrel4Unknown Status1
DB11312Protein C4Enrolling by Invitation1
DB11311Prothrombin4Enrolling by Invitation1
DB06228Rivaroxaban4Completed2
DB09153Sodium Chloride4Terminated1
DB09099Somatostatin4Completed1
DB00302Tranexamic acid4Completed3
DB00302Tranexamic acid4Terminated1
DB00302Tranexamic acid4Unknown Status2
DB00752Tranylcypromine4Completed1
DB00682Warfarin4Completed2
DB09145Water4Enrolling by Invitation1
DB00945Acetylsalicylic acidNot AvailableActive Not Recruiting1
DB00513Aminocaproic AcidNot AvailableCompleted1
DB11121ChloroxylenolNot AvailableUnknown Status1
DB00758ClopidogrelNot AvailableCompleted1
DB12362Diaminopropanol tetraacetic acidNot AvailableRecruiting1
DB01225EnoxaparinNot AvailableCompleted1
DB00783EstradiolNot AvailableCompleted1
DB00998FrovatriptanNot AvailableCompleted1
DB01109HeparinNot AvailableRecruiting1
DB00788NaproxenNot AvailableCompleted1
DB00727NitroglycerinNot AvailableUnknown Status1
DB00213PantoprazoleNot AvailableUnknown Status1
DB01022PhylloquinoneNot AvailableWithdrawn1
DB09528PhylloquinoneNot AvailableWithdrawn1
DB02638TerlipressinNot AvailableNot Yet Recruiting1
DB08816TicagrelorNot AvailableCompleted1
DB06822TinzaparinNot AvailableUnknown Status1
DB00302Tranexamic acidNot AvailableCompleted1
DB00302Tranexamic acidNot AvailableNot Yet Recruiting1